NewsBang
Search
Sign In
Sign In
Sources
4 Total Sources
Skyhawk Reports 69% Huntingtin Reduction for SKY-0515 as 12-Month HD Data Support Phase 2/3 Push
All
4
Others
4
en.hdbuzz.net
1d ago
Skyhawk's SKY-0515 Shows 69% Huntingtin Reduction, Encouraging Clinical Trends in 12-Month Phase 1/2 Data
recnews.it
1d ago
Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease - Rec News
weeklyvoice.com
1d ago
Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease – Weekly Voice
hda.org.uk
1d ago
Huntington's Disease Association - Improvement in Huntington's disease patients in Skyhawk Therapeutics trial